Search Results - "Seidman, A.D"

A summary of head-to-head comparisons of patient (pt) risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer (EBC) by Varga, Z, McCullough, D, Lau, A, Stöppler, M, Baehner, F.L, Seidman, A.D

Get full text

Prognostic Implications of Receptor Status and Extracranial Disease in Patients With Breast Cancer Brain Metastases Treated With Stereotactic Radiosurgery by Yang, T, Oh, J, Folkert, M, Morikawa, A, Seidman, A.D, Yamada, Y, Chan, T.A, Beal, K

Get full text

Proton Craniospinal Irradiation for Patients with Solid Tumor Leptomeningeal Metastasis- Final Analysis of a Phase II Study by Yang, J.T., Yerramilli, D., Pentsova, E., Wolden, S.L., Young, R.J., Correa, D., Zhang, Z., Zheng, J., Baser, R.E., Warner, A. Betof, Yu, H., Kris, M.G., Seidman, A.D., Wilcox, J.A., Malani, R., Powell, S.N., Boire, A.

“…Solid tumor leptomeningeal metastasis (LM) is associated with limited survival. We evaluated whether proton craniospinal irradiation (pCSI) would result in…”
Get full text

Heightened Sensitivity of Germline BRCA Mutant Patients Treated With Concurrent or Adjuvant PARP Inhibition and Radiotherapy for Brain Metastases by Santos, P., Imber, B.S., Lapen, K., Pike, L.R.G., Moss, N., Seidman, A.D., Beal, K.

“…Limited data exist regarding the effect of radiotherapy (RT) and poly (ADP-ribose) polymerase inhibition (PARPi) for brain metastases (BM). However, RT is…”
Get full text

Phase II Randomized Trial Comparing Proton Craniospinal Irradiation with Photon Involved-Field Radiotherapy for Patients with Solid Tumor Leptomeningeal Metastasis by Yang, J.T., Wijetunga, N.A., Pentsova, E., Wolden, S.L., Young, R.J., Correa, D., Zhang, Z., Zheng, J., Warner, A. Betof, Yu, H., Kris, M.G., Seidman, A.D., Malani, R., Lin, A., DeAngelis, L., Lee, N.Y., Powell, S.N., Boire, A.

Get full text

Nanoparticle albumin-bound paclitaxel in 3 dosing schedules with bevacizumab as first line therapy for HER2-negative metastatic breast cancer: an interim safety analysis by Seidman, A.D, Conlin, A.K, Moynahan, M.E, Bach, A, Troso-Sandoval, T, Sugarman, S, Forero, A, Kerr, R, Wright, G, Hudis, C.A

Get full text

Final Analysis of Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression Trial - A Randomized Study of Stereotactic Body Radiotherapy for Oligoprogressive Metastatic Lung and Breast Cancers by Tsai, C.J., Yang, J.T., Guttmann, D.M., Shaverdian, N., Eng, J., Yeh, R., Girshman, J., Das, J., Gelblum, D., Xu, A.J., Namakydoust, A., Iqbal, A., Mann, J.M., Preeshagul, I., Hajj, C., Gillespie, E.F., Modi, S., Dang, C., Drullinsky, P., Zhi, W., LaPlant, Q., Rimner, A., Shin, J.Y., Wu, A.J., Ng, K., Gucalp, A., Khan, A.J., Sanford, R., Bromberg, J., Seidman, A.D., Traina, T.A., Gomez, D.R., Flynn, J., Zhang, Z., Patel, J.A., Berger, M., Reis-Filho, J.S., Lee, N.Y., Riaz, N., Robson, M.E., Rudin, C.M., Powell, S.N.

“…To assess if stereotactic body radiotherapy (SBRT) for oligoprogressive metastatic lung or breast cancer prolongs progression-free survival (PFS), overall…”
Get full text

Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer by Morris, Patrick G., Rota, Selene, Cadoo, Karen, Zamora, Stephen, Patil, Sujata, D'Andrea, Gabriella, Gilewski, Theresa, Bromberg, Jacqueline, Dang, Chau, Dickler, Maura, Modi, Shanu, Seidman, Andrew D., Sklarin, Nancy, Norton, Larry, Hudis, Clifford A., Fornier, Monica N.

“…Overexpression and activation of tyrosine kinase Src has been linked to breast carcinogenesis and bone metastases. We conducted a phase II trial in patients…”
Get full text

Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression ― Interim Analysis of the First Randomized Study of Stereotactic Body Radiotherapy in Patients With Oligoprogressive Metastatic Cancers of the Lung and Breast by Tsai, C.J., Yang, J.T., Guttmann, D.M., Shaverdian, N., Shepherd, A.F., Eng, J., Gelblum, D., Xu, A.J., Namakydoust, A., Iqbal, A., Mann, J.M., Preeshagul, I., Hajj, C., Gillespie, E.F., Sugarman, S., Modi, S., Dang, C., Drullinsky, P., Yeh, R., Girshman, J., Das, J., Zhi, W., LaPlant, Q., Reyngold, M., Rimner, A., Shin, J.Y., Wu, A.J., Ng, K., Gucalp, A., Sanford, R., Khan, A.J., Bromberg, J., Seidman, A.D., Comen, E., Traina, T.A., Gomez, D.R., Zhang, Z., Robson, M.E., Rudin, C.M., Powell, S.N.

“…We hypothesize that there is an oligoprogressive state in metastatic cancer, in which disease control can be improved with local therapy to progressive lesions…”
Get full text

P227 - A summary of head-to-head comparisons of patient (pt) risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer (EBC) by Varga, Z., McCullough, D., Lau, A., Stöppler, M., Baehner, F.L., Seidman, A.D.

Get full text

Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840 by Lichtman, S.M., Hurria, A., Cirrincione, C.T., Seidman, A.D., Winer, E., Hudis, C., Cohen, H.J., Muss, H.B.

“…Two Cancer and Leukemia Group B (CALGB) studies were utilized to determine the efficacy and tolerability of paclitaxel (Taxol) in older patients with…”
Get full text

ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC) by Tripathy, D., Tolaney, S.M., Seidman, A.D., Anders, C.K., Ibrahim, N.K., Rugo, H.S., Twelves, C.J., Dieras, V., Müller, V., Hannah, A.L., Tagliaferri, M.A., Cortes Castan, J.

Get full text

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer by Fornier, M.N., Morris, P.G., Abbruzzi, A., D'Andrea, G., Gilewski, T., Bromberg, J., Dang, C., Dickler, M., Modi, S., Seidman, A.D., Sklarin, N., Chang, J., Norton, L., Hudis, C.A.

“…SRC plays an important role in the pathogenesis of metastatic breast cancer (MBC). In preclinical models, paclitaxel and the oral SRC inhibitor dasatinib…”
Get full text

Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays by Brogi, E., Murphy, C.G., Johnson, M.L., Conlin, A.K., Hsu, M., Patil, S., Akram, M., Nehhozina, T., Jhaveri, K.L., Hudis, C.A., Seidman, A.D.

“…Development of brain metastasis in patients with breast carcinoma correlates with poor outcome. Identification of tumor characteristics associated with breast…”
Get full text

Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate by Fornier, M. N., Seidman, A. D., Schwartz, M. K., Ghani, F., Thiel, R., Norton, L., Hudis, C.

“…Purpose: We explored the relationship between circulating HER2 extracellular domain (ECD) and tissue HER2 status as determined by immunohistochemistry (IHC)…”
Get full text

A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group by Miller, K.D., O’Neill, A., Perez, E.A., Seidman, A.D., Sledge, G.W.

“…E2104 was designed to evaluate the safety of two different strategies incorporating bevacizumab into anthracycline-containing adjuvant therapy as a precursor…”
Get full text

Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer by Seidman, A.D., Brufsky, A., Ansari, R.H., Hart, L.L., Stein, R.S., Schwartzberg, L.S., Stewart, J.F., Russell, C.A., Chen, S.-C., Fein, L.E., De La Cruz Vargas, J.A., Kim, S.-B., Cavalheiro, J., Zhao, L., Gill, J.F., Obasaju, C.K., Orlando, M., Tai, D.F.

“…Safety and efficacy of gemcitabine plus docetaxel (GD) and capecitabine plus docetaxel (CD) were compared in patients with metastatic breast cancer, where the…”
Get full text

Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer by Murphy, C. G, Khasraw, M, Seidman, A. D

Get full text